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Estrogen treatment causes significant hypophosphatemia in
patients. To determine the mechanisms responsible for
this effect, we injected ovariectomized rats with either
17b-estradiol or vehicle for three days. Significant renal
phosphate wasting and hypophosphatemia occurred in
estrogen-treated rats despite a decrease in their food intake.
The mRNA and protein levels of the renal proximal tubule
sodium phosphate cotransporter (NaPi-IIa) were significantly
decreased in estradiol-treated ad-libitum or pair-fed groups.
Estrogen did not affect NaPi-III or NaPi-IIc expression. In
ovariectomized and parathyroidectomized rats, 17b-estradiol
caused a significant decrease in NaPi-IIa mRNA and protein
expression compared to vehicle. Estrogen receptor alpha
isoform blocker significantly blunted the anorexic effect of
17b-estradiol but did not affect the downregulation of
NaPi-IIa. Our studies show that renal phosphate wasting
and hypophosphatemia induced by estrogen are secondary
to downregulation of NaPi-IIa in the proximal tubule.
These effects are independent of food intake or
parathyroid hormone levels and likely not mediated through
the activation of estrogen receptor alpha subtype.
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Inorganic phosphorus (Pi) is essential for various important
functions, including synthesis of cellular energy (ATP),
intracellular signaling, protein synthesis, as well as bone
matrix and phospholipid synthesis. Published reports
indicate that Pi homeostasis is maintained and controlled
efficiently in response to changes in Pi intake or physiological
conditions. Intestinal absorption and renal excretion or
reabsorption are the major regulatory steps in Pi home-
ostasis.1–3 In both kidney and small intestinal epithelium, Pi
absorption is mediated via the type II Naþ -dependent
phosphate cotransporter from SLC34 family,4 which includes
IIa, IIb, and IIc variants. The intestinal absorption of Pi is
mediated predominantly through type IIb (NaPi-IIb),5
whereas in the kidney, both NaPi-IIa and NaPi-IIc are
expressed in the brush-border membrane of proximal tubule
cells and mediate the reabsorption of filtered Pi from the
tubular filtrate.6–8 The increased urinary Pi excretion in NaPi-
IIa-knockout mice suggests that NaPi-IIa is the limiting
barrier for Pi reabsorption in the renal proximal tubule.9,10
NaPi-IIa is regulated by several factors, including glucocorti-
coids,11 epidermal growth factors,12,13 parathyroid hormone
(PTH),14–16 vitamin D3,17 thyroid hormone,18,19 dopamine,20
metabolic acidosis,21 dietary phosphate,10,22 and phosphato-
nins.23 Phosphatonins belong to a new class of phosphate-
regulating factors, which include fibroblast growth factor-23
(FGF-23) and secreted frizzled-related protein 4. These
factors were reported to be associated with hypophos-
phatemic diseases.23 In the small intestine, NaPi-IIb is also
expressed in apical membranes of the intestinal villi and is
regulated by the same above factors, mostly dietary
phosphate,24,25 epidermal growth factor,26 vitamin D3,25
glucocorticoid,27 and estrogen (EST).28
Pi and calcium are the two major minerals that play an
important role in bone matrix and bone mineralization.
Several pathophysiologic states such as metabolic acidosis are
associated with enhanced urinary Pi and calcium wasting and
bone loss.29–31 Sex steroids depletion, mainly ESTs, has been
suggested as a major factor in bone minerals loss in
postmenopausal osteoporosis.32,33 However, the effect of
sex steroids on renal Pi handling is poorly understood.
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Clinical studies have shown that women treated with ESTs
exhibited hypophosphatemia;34–38 in some studies, a reduc-
tion in proximal tubular Pi reabsorption was observed.35,36,38
Conversely, EST-depleted patients showed elevated plasma
levels of Pi and increased rate of proximal tubule Pi
reabsorption.34 In rats, recent studies demonstrated that
EST stimulated the expression of small intestine NaPi-IIb.28
In the kidney, however, other studies reported that EST
treatment of ovariectomized (OVX) rats caused a significant
decrease in Pi uptake by the brush-border membrane vesicles
of proximal tubules as compared to control animals.39 These
studies, however, did not examine the molecular basis and
signaling pathways responsible for the reduction in Pi uptake
by EST in the proximal tubule cells.
Thus, the aim of these studies was to examine the effects
of female sex steroids on renal Pi handling, various Pi
transporters, and systemic phosphate homeostasis. Toward
this end, OVX rats, with and without parathyroidectomy,
were treated with progesterone or EST in the absence or
presence of EST receptor-a isoform (ERa) blocker. The
results demonstrated that EST, but not progesterone,
specifically downregulates the expression of NaPi-IIa and
causes phosphaturia. This effect is independent of PTH or
alteration in Pi intake, and is not mediated through ERa.
RESULTS
Blood electrolytes composition in vehicle- vs EST-treated rats
Blood chemistry data shown in Table 1 indicate that rats
treated with EST for 3 days showed normal electrolytes
composition, except for a significant hypophosphatemia
(Po0.05), as compared to vehicle-injected rats.
Food intake, urinary Pi, and calcium excretion in response to
EST
The results depicted in Figure 1 indicate a significant
reduction in food intake, which occurred as early as 24 h
after EST injection (from 21±0.9 g at baseline to 14±1.1 g
after 24 h of EST, Po0.001, Figure 1a), and further decreased
to a lower level after 3 days of EST treatment (6.6±0.96 g,
Po0.0001, n¼ 4 rats in each group, Figure 1a). Food intake
in vehicle-treated group remained unchanged for the
duration of the treatment (20±0.43 g before and 19±1.0 g
Table 1 | Blood composition of OVX rats treated with EST or its vehicle for 3 days
Glucose (mg/dl) BUN (mg/dl) Creatinine (mg/dl) Na+ (mEq/l) K+ (mEq/l) CI (mEq/l) CO2 (mEq/l) Pi (mEq/l)
Vehicle 154±8.34 20±1.5 0.35±0.03 142±0.81 5.65±0.10 100±0.65 20±2.7 7.78±0.29
EST 139±3.6 17±1.6 0.36±0.02 140±0.20 5.62±0.20 100±0.50 20±0.40 7.02±0.17
P NS NS NS NS NS NS NS 0.049
BUN, blood urea nitrogen; EST, estrogen; NS, nonsignificant; OVX, ovariectomized.
Data are mean±s.e., n=4 rats in each group.
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Figure 1 | Effects of EST on food intake and urinary Pi and calcium excretion. OVX rats were placed in metabolic cages and had free access
to regular rat chow and distilled water. After 3 days, rats were injected with EST or its vehicle, and (a) food intake, (b) urinary inorganic
phosphate (Pi) excretion, and (c) urinary calcium excretion were monitored daily for an additional 3 days. n¼ 4 rats in each group. Significance
between baseline and EST treatment at different time points is indicated.
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after 3 days of vehicle treatment, P40.05, n¼ 4 rats,
Figure 1a).
Despite the sharp reduction in food intake described
above (Figure 1a), EST-treated rats exhibited a significant
phosphaturia as shown by a sustained or even a slight
increase in urinary Pi excretion after EST injection (from
0.88±0.13 mg/24 h at baseline to 1.36±0.14 mg/day after
24 h, Po0.05, Figure 1b and to 1.11±0.23 mg/24 h after 3
days of treatment, P40.05, n¼ 4 rats in each time point,
Figure 1b).
Unlike Pi excretion, urinary calcium excretion decreased
sharply within the first 24 h of EST treatment (from
3.65±0.31 mg/24 h at baseline to 1.88±0.45 mg/24 h after
24 h of EST treatment, Po0.02, Figure 1c), and further
decreased to an even lower level after 3 days of EST injection
(0.14±0.05 mg/24 h, Po0.001, n¼ 4 rats, Figure 1c). Urin-
ary calcium excretion remained unchanged for the duration
of the experiment in vehicle-injected animals
(3.90±0.75 mg/24 h before and 3.98±0.58 mg/24 h after
vehicle injections, P40.05, n¼ 4 rats, Figure 1c). The
decrease in the urinary calcium excretion, which parallels
the reduction in food intake, indicates an increase in renal
calcium conservation in response to EST treatment.
NaPi-IIa expression in response to EST treatment
The mRNA expression and protein abundance of NaPi-IIa
were examined by northern hybridization and immunoblot-
ting, respectively, using total RNA and membrane proteins
harvested from renal cortex of vehicle- and EST-treated rats.
The results depicted in Figure 2 indicate a significant decrease
in NaPi-IIa mRNA expression in response to 3 days of EST
injections (32±7 vs 100±23% in vehicle-treated animals,
Po0.04, n¼ 4 rats in each group, Figure 2a and b). This
decrease in NaPi-IIa mRNA correlates with a significant
reduction in its protein abundance in EST-injected rats, as
shown by a decrease in the expression levels of both 50 kDa
band (50±6 vs 100±5% in vehicle group, Po0.01, n¼ 4
rats, Figure 2c (upper panel) and d) and 80–90 kDa band
(45±8 vs 100±7% in vehicle group, Po0.01, n¼ 4 rats,
Figure 2c (upper panel) and d) of NaPi-IIa protein. A parallel
Coomassie blue-stained gel indicates the equity of the protein
loading between different lanes (Figure 2c, lower panel).
Progesterone treatment of OVX rats did not alter the
mRNA expression or protein abundance of NaPi-IIa
compared to its vehicle group (data not shown).
Cortical NHE3 and AQP-1 expression in response to EST
treatment
Using the same total membrane protein fractions used above
for NaPi-IIa, we examined the protein abundance of cortical
NHE3 and aquaporin-1 (AQP-1) in EST- vs vehicle-treated
animals. The results shown in Figure 3 indicate that EST
treatment did not alter the protein abundance of NHE3
(96±13 vs 100±8% in vehicle group, P40.05, n¼ 4 rats in
each group, Figure 3a and b) or that of AQP-1 (109±8 vs
100±8% in vehicle group, P40.04, n¼ 4 rats in each group,
Figure 3c and d) in the renal cortex.
Effects of EST treatment on Pi transporters in a pair-feeding
protocol
To determine whether the downregulation of NaPi-IIa by
EST is independent of changes in food intake, OVX rats were
treated with EST for 3 days and compared to vehicle-injected
rats that had access to the same amount of food consumed by
EST rats (pair-feeding, PF) as shown in Figure 4. In this
setting, EST reproducibly decreased food intake from
15±0.68 to 5.06±0.43 g/24 h during 3 days of treatment
(Figure 4a). Vehicle-treated rats were subjected to daily food
restriction as described in Materials and Methods. Food
consumption was reduced from 15±0.46 to 5.2±0.32 g/24 h
during 3 days of treatment (Figure 4a). Urinary Pi excretion
correlated with decreased food intake in vehicle-treated rats
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Figure 2 | mRNA expression and protein abundance of NaPi-IIa. (a) Northern hybridization of NaPi-IIa mRNA in the renal cortex of rats
injected with EST vs vehicle. 28S rRNA was used as a constitutive gene for the control of the equity of RNA loading into northern gels.
(b) Corresponding densitometric analysis showing the mean of NaPi-IIa mRNA-to-28S rRNA ratio. (c) Immunoblot showing the abundance
of NaPi-IIa protein in membrane fractions isolated from renal cortex of vehicle- and EST-treated rats (upper panel), and a Coomassie
blue-stained gel picture showing the equity of protein loading (lower panel). (d) The average of the densitometric analysis of NaPi-IIa
bands (50 and 80–90 kDa). Each lane was loaded with 30 mg of total RNA or 25 mg membrane proteins from a different rat. n¼ 4 rats
in each group, *Po0.01 vs vehicle.
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(from 0.51±0.05 mg/24 h before to 0.09±0.04 mg/24 h after
food restriction, Po0.001, n¼ 4 rats, Figure 4b), whereas it
remained unchanged or even slightly higher in EST-injected
rats (from 0.45±0.03 mg/24 h before to 0.61±0.05 mg/24 h
after EST treatment, n¼ 4 rats, Figure 4b).
The results depicted in Figure 5 indicate a significant
reduction in the mRNA expression of NaPi-IIa in response to
EST treatment (56±4 vs 100±7% in vehicle-PF group,
Po0.003, n¼ 4 rats in each group, Figure 5a). This correlates
with a significant decrease in NaPi-IIa protein abundance, as
indicated by the immunoblot depicted in Figure 5c (57±17
vs 100±6% in vehicle-PF group, Po0.05, n¼ 4 rats in each
group, Figure 5c and d). A parallel Coomassie blue-stained
gel indicates the equity of the protein loading between
different lanes (data not shown).
The expression of other transporters involved in Pi
reabsorption in the proximal tubule was also examined
under the above experimental conditions. The results shown
in Figure 6 indicate that EST treatment did not alter the
mRNA expression of NaPi-IIc, another apical Naþ -depen-
dent Pi transporter7,8 (110±12 vs 100±6.9% in vehicle-PF
group, P40.05, n¼ 4 rats in each group, Figure 6), and did
not alter the expression of type III Naþ -dependent Pi
transporter (PiT1), which is localized to the basolateral
membrane of proximal tubule cells8 (91±9 vs 100±5% in
vehicle-PF group, P40.05, n¼ 4 rats in each group, Figure 6).
Lastly, the effect of EST on the expression of klotho and
Naþ /Hþ exchanger regulatory factor 1 (NHERF1) was
examined by northern hybridization. The results indicate that
EST treatment did not affect the mRNA expression of klotho
(101±8 vs 100±5.9% in vehicle-PF group, P40.05, n¼ 4
rats in each group, Figure 6b) or that of NHERF1 (115±14
vs 100±2.5% in vehicle-PF group, P40.05, n¼ 4 rats in each
group, Figure 6b).
Effects of EST on NaPi-IIa expression in OVX–PTX rats
To determine whether PTH plays any role in the down-
regulation of NaPi-IIa by EST, we repeated these experiments
in rats deficient in PTH. Toward this end, OVX and
parathyroidectomized (PTX) rats were subjected to either
vehicle or EST treatment for 3 days, as described in Materials
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Figure 3 | Protein abundance of NHE3 and AQP-1. (a and c) Immunoblots showing the abundance of NHE3 and AQP-1 water channel
proteins in membrane fractions isolated from renal cortex of vehicle- and EST-treated rats. (b and d) The average of the densitometric analysis
of NHE3 and AQP-1 (28 kDa) bands. n¼ 4 rats in each group. Each lane was loaded with 40 mg (NHE3) or 5 mg (AQP-1) of membrane proteins
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Figure 4 | Effects of EST on food intake and urinary Pi excretion in a PF protocol. OVX rats were placed in metabolic cages and had
free access to regular rat chow and distilled water. After 3 days, rats were injected with EST or its vehicle. At time zero, vehicle-treated
rats received the same amount of food (PF) that is consumed by EST-injected rats. (a) Food intake and (b) urinary inorganic phosphate (Pi)
excretion were monitored daily for an additional 3 days. n¼ 4 rats in each group. Significance between baselines and EST or vehicle
treatments at different time points is indicated. *Po0.01 and **Po0.001 vs vehicle.
1144 Kidney International (2008) 73, 1141–1150
o r i g i n a l a r t i c l e S Faroqui et al.: Estrogen causes renal phosphate wasting
and Methods, and used to examine the expression of NaPi-IIa
in the renal cortex. The results shown in Figure 7 indicate the
following: first, OVX–PTX rats consume significantly less
food than OVX rats (6.94±0.16 g/24 h, Figure 7a, vs
21±0.9 g/24 h, Figure 1a, Po0.001, n¼ 4–5 rats in each
group). Second, EST treatment of OVX–PTX rats surprisingly
did not affect food intake (6.94±0.16 g/24 h before and
6.73±0.11 g/24 h after 3 days of EST treatment, P40.05,
n¼ 5 rats, Figure 7a) as compared to EST-treated OVX
animals (Figure 1a). However, EST caused a significant
increase in urinary Pi excretion as shown in Figure 7b. Lastly,
EST treatment of OVX–PTX rats was associated with a
significant reduction in NaPi-IIa mRNA expression levels as
compared to vehicle treatment (from 100±12 to 53±10%,
Po0.02, n¼ 4–5 rats in each group, Figure 7a and b). This
effect correlated with a significant reduction in NaPi-IIa
protein abundance in EST-treated animals (48±11 vs
100±5% in vehicle-injected rats, Po0.03, n¼ 4–5 rats in
each group, Figure 7c (upper panel) and d). A parallel
Coomassie blue-stained gel indicates the equity of the protein
loading between different lanes (Figure 7c, lower panel).
Effect of EST in the presence of ERa inhibitor
Effect of EST on food intake in the presence of ERa
blocker. EST acts on its target cells through different
receptor subtypes, including ERa, ERb, and GRP.40–43 In the
next experiments, we tested the role of ERa in EST-induced
phosphaturia and NaPi-IIa downregulation. Accordingly,
OVX rats were placed in metabolic cages and treated with
EST, ICI182,780, ICIþ EST, or their vehicle as described in
Materials and Methods. The results depicted in Figure 8
indicate that EST reproducibly decreased food intake from
18±0.68 g/24 h at baseline to 5±0.85 g/24 h after 3 days of
treatment (Po0.001, n¼ 4 rats, Figure 8a and b). This effect
is partially, but significantly, blocked by the presence of ERa
inhibitor, as food intake decreased from 17±0.68 g/24 h at
baseline to 9±1.14 g/24 h after 3 days of ICIþ EST treatment
(Po0.01, n¼ 6 rats, Figure 8a and b). The treatment of the
animals with ICI alone for 3 days did not significantly alter
food intake (16±0.56 g/24 h before and 14±0.86 g/24 h after
3 days of ICI treatment, P40.05, n¼ 6 rats, Figure 8a and b).
The food intake in vehicle-injected rats remained unchanged
for the duration of the experiment (17±1.1 g/24 h before and
16±0.89 g/24 h after 3 days of vehicle treatment, P40.05,
n¼ 4 rats, Figure 8b). It should be noted that the results
described above for ICI alone and ICIþ EST are actually
pooled results of two different doses of ICI (300 and 600 mg/
rat/day), which showed similar effects on food intake (n¼ 3
OVX rats in each group).
Effect of EST on NaPi-IIa expression in the presence of ERa
blocker. The expression of NaPi-IIa was examined in the
renal cortex of rats treated with ICI182,780 alone, ICIþ EST,
or their vehicle by northern hybridization and immunoblot-
ting. The results shown in Table 2 indicate that the mRNA
expression level of NaPi-IIa is significantly decreased in
ICIþ EST rats as compared to vehicle (46±1.36 vs
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100±5.5%, Po0.001, n¼ 3–4 rats in each group, Table 2).
ICI treatment alone did not significantly alter the mRNA
expression levels of NaPi-IIa (85±3.4 vs 100±5.5% in
vehicle group, P40.05, n¼ 3 rats in each group, Table 2).
Similarly, the protein abundance of NaPi-IIa decreased
significantly in ICIþ EST rat as compared to vehicle (51±7
vs 100±6%, Po0.02, n¼ 3 rats in each group, Table 2),
whereas it remained unchanged in ICI alone vs vehicle-
treated rats (Table 2).
DISCUSSION
This is the first report demonstrating that EST can regulate
phosphate homeostasis in Sprague Dawley rat, and is highly
relevant to the postmenopausal women taking EST hormone
to maintain their bone health. Increased bone turnover and
loss of bone density are common in postmenopausal women.
EST therapy reduces bone resorption and prevents bone loss
and osteoporosis.44 This process has been advanced to
explain the decrease in circulating levels of calcium and
inorganic phosphate (Pi) in postmenopausal women on EST
replacement therapy.36,37,45
It is well accepted that the proximal tubular reabsorption
of Pi is the major determinant of Pi homeostasis. Given the
impressive downregulation of the Naþ -dependent phosphate
(Pi) transporter NaPi-IIa and the subsequent renal Pi wasting
(Figure 1b) and hypophosphatemia (Table 1) in rats treated
with EST, we suggest that the hypophosphatemic effect of
EST replacement in postmenopausal women is predomi-
nantly mediated via its effect on the kidney.
Earlier studies showed that EST treatment of rats was
associated with an inhibition of Pi uptake in brush-border
membrane vesicles harvested from the renal cortex.39
However, those studies did not examine the role of EST on
the expression of the renal phosphate-dependent transporters
and systemic phosphate homeostasis. Our results demons-
trate that EST significantly downregulates the mRNA
expression and protein abundance of NaPi-IIa (Figure 2), a
major Naþ -dependent Pi transporter exclusively expressed in
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Figure 8 | Effect of EST on food intake in the presence or absence of ERa inhibitor. (a) OVX rats were placed in metabolic cages
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the apical membrane of proximal tubule cells.9,10 Unlike EST,
progesterone treatment of OVX rats did not alter Pi
metabolism and did not affect the expression of NaPi-IIa.
This effect of EST is specific to NaPi-IIa, as the expression
levels of other Pi-dependent (PiT1 and NaPi-IIc) or Pi-
independent (NHE3 and AQP-1) transporters expressed in
the proximal tubule were not altered in response to EST
treatment (Figures 3 and 6).
In these studies, we did not examine the transport activity
of NaPi-IIa in EST-treated rats; however, based on studies
showing that Pi uptake is significantly inhibited in brush-
border membrane vesicle of EST-injected arts,39 and based on
the fact that the genetic deletion of NaPi-IIa caused a
significant and uncompensated phosphaturia,9 one can
conclude that impairment in NaPi-IIa transport activity
should certainly correlate with the decrease in its expression
to account for increased Pi excretion in EST-injected rats.
Hence, EST-induced renal Pi wasting is likely secondary to
the downregulation of NaPi-IIa in the proximal tubule.
EST is an important physiological regulator involved in
the modulation of several behavioral and hormonal func-
tions, indicating that the mechanisms by which EST regulates
Pi metabolism could be complex, and could involve direct
and/or indirect effect(s). EST has been shown to induce
anorexia and decrease appetite.46–48 This effect is clearly
reproduced in our studies (Figures 1a and 4a). However, it is
unlikely that the downregulation of NaPi-IIa is secondary to
the alteration in food intake, as the phosphaturic effect of
EST persisted even when EST-treated rats were compared to
pair-fed rats injected with vehicle (Figures 4 and 5). Further,
an eventual role of PTH, which is a potent inhibitor of NaPi-
IIa expression and activity,14–16 is excluded in these studies.
In fact, our studies performed in PTH-deficient (PTX) OVX
rats exhibited a significant downregulation of NaPi-IIa
(Figure 7). These findings are in support of the inhibition
of Pi uptake in brush-border membrane vesicle previously
reported in OVX-PTX rats.39 Finally, NaPi-IIa expression is
downregulated in metabolic acidosis;21 however, EST-treated
rats did not show any acid–base abnormality, as indicated by
normal serum total CO2 levels shown in Table 1.
In addition to the PTH, studies have demonstrated that
dopamine is a potent phosphaturic hormone. These studies
demonstrated that dopamine regulates renal Pi transport by
an autocrine/paracrine mechanism.20 The phosphaturic effect
of dopamine is induced by both dopamine and D1-like
receptor agonists, and inhibited by D1-like antagonists.20
Furthermore, studies have shown that EST upregulates the
expression and activity of D1A dopamine receptor,49 and that
the incubation of human neuroblastoma cells with EST
caused a significant increase in dopamine levels, elicited by
increased dopamine synthesis and decreased dopamine
catabolism.50 However, whether EST regulates dopamine
activity and/or metabolism in the renal proximal tubule, and
whether dopamine mediates the phosphaturic effects of EST
remain to be demonstrated in future studies. Lastly, FGF-23
is a potent regulator of Pi metabolism by directly inhibiting
Pi reabsorption in the proximal tubule.51 Whether the effect
of EST is mediated through the stimulation of FGF-23
remains to be determined.
Unlike other hormones, the effects of sex steroids on salt
transport or other functions of proximal tubule cells have not
been extensively studied. Several ligand-binding studies
demonstrated the presence of EST receptor in both the
cytosol and nucleus of rat kidney cells.52,40 These receptors
are expressed mainly in S1 and S2 segments of rat proximal
tubule.41 The majority of EST response is mediated through
two different forms of EST receptor usually referred to as ERa
and ERb, each encoded by a separate gene. ERa and ERb are
ligand-regulated transcription factors that mediate genomic
effects of different estrogenic molecules, including 17b-
estradiol.42 Interestingly, downregulation of NaPi-IIa and
subsequent phosphaturia by EST are independent of ERa
activation. This is clearly shown by our studies using
ICI182,780, a potent inhibitor of ERa,43,53–55 which sig-
nificantly blunted the anorexic effect of EST (Figure 8),
without preventing the downregulation of NaPi-IIa (Table 2).
Whether the effect of EST on Pi transport is mediated
through ERb remains to be determined.
It should be noted that there is now strong evidence that
EST can also exert a rapid and non-genomic effect on certain
target tissues. These include activation of G protein-coupled
receptors such as GPR 3056–58 and mobilization of intracel-
lular calcium,57 stimulation of adenylate cyclase and cAMP
production,58 and activation of the mitogen-activated
protein kinase signaling pathways.56 It remains to be
determined whether these pathways contribute to the
phosphaturic effect of EST in rats.
Finally, we should emphasize that the hypophosphatemic
and hyperphosphaturic effect of EST has been reported in
clinical settings. Several studies have demonstrated that
administration of EST to postmenopausal women is
associated with hypophosphatemia which, in certain cases,
is secondary to a reduction in Pi reabsorption in the proximal
tubule.35,36,38 A significant decrease in serum Pi levels was
reported in male patients with metastatic prostate cancer
treated with EST.35 On the other hand, it was found that
EST-deficient patients exhibited significant hyperphos-
phatemia secondary to increased proximal tubule Pi
reabsorption.34
Table 2 | Effects of EST on NaPi-IIa mRNA expression and
protein abundance in the presence of ERa blocker ICI182,780
NaPi-IIa
mRNA Protein
Vehicle 100±5.5 100±6
ICI182,780 85±3.4 95±4
ICI+EST 46±1.36a,b 51±7a,c
ERa, estrogen receptor-a; EST, estrogen.
Data are mean±s.e. expressed as % of vehicle. n=3–4 rats in each group.
aPo0.001 vs ICI alone.
bPo0.0001 vs vehicle.
cPo0.03 vs vehicle.
Kidney International (2008) 73, 1141–1150 1147
S Faroqui et al.: Estrogen causes renal phosphate wasting o r i g i n a l a r t i c l e
In conclusion, EST treatment of OVX rats caused
significant hyperphosphaturia and hypophosphatemia, which
were secondary to the downregulation of a major apical Pi-
dependent transporter NaPi-IIa in the renal proximal tubule.
The effect of EST on this transporter is not mediated through
changes in food behavior or alterations in the circulating
levels or activity of PTH, and is likely not mediated through
ERa. It is highly plausible that the downregulation of NaPi-
IIa in the proximal tubule is the molecular basis of
hyperphosphaturia/hypophosphatemia observed in patients
subjected to EST therapy. In treating postmenopausal women
or patients with breast or prostate malignancy with EST-
containing hormonal replacement regimens, health-care
professionals should monitor and pay attention to the renal
handling of phosphate very closely.
MATERIALS AND METHODS
Animal treatments
The experimental protocols were approved by Institutional Animal
Care and Use Committee of University of Cincinnati. OVX Sprague
Dawley rats (Harlan, Indianapolis, IN, USA) were housed two rats
per cage with free access to rat chow and distilled water, and
maintained in a temperature-controlled room regulated on a 12-h
light/dark cycle for 1 week before and during the following
treatments.
EST and progesterone treatment. OVX rats were placed in
metabolic cages and allowed free access to food and water. After 3–4
days of adjustment to metabolic cages, rats were randomly divided
into two groups and injected subcutaneously with either 17b-
estradiol (15 mg/100 g body weight/day) or its vehicle (sesame oil).
To determine the role of PTH in the observed effects of EST on Pi
excretion, the above experiment was repeated in OVX and PTX rats
(Harlan). In another set of studies, OVX rats were treated similarly
in metabolic cages and injected subcutaneously with either
progesterone (1.6 mg/100 g body weight/day) or its vehicle (sesame
oil). The rats remained on food and water for an additional 3 days.
EST treatment in a PF protocol. As EST treatment of OVX rats
is associated with a significant reduction in food intake (Figure 1),
another set of OVX rats housed in metabolic cages were injected
with either EST or its vehicle. However, the vehicle-treated rats were
also subjected to daily food restriction, as they were given the same
amount of food consumed by EST-treated rats determined during
the first experiment (Figure 1a).
EST treatment in the presence of ERa inhibitor. In this
experiment, another set of OVX rats were housed in metabolic cages
and divided into four groups. The first group (EST) was injected
with EST (15 mg/100 g body weight/day), the second group was
injected with ERa blocker ICI182,780 or Fulvestrant alone,43,53–55
the third group was injected with ICI 2 h before EST injection
(ICIþ EST), and the fourth group was injected with the vehicle
(ethanol/propylene glycol, 1:4 v/v). To minimize the number of rats
used, EST was also dissolved in ethanol/propylene glycol solution. It
should be noted that two doses of ICI were used in these studies
both in ICI alone and ICIþ EST groups (that is, 300 and 600 mg/rat/
day).
During each of the above studies, food and water intake and
urine volume were measured daily. At the end of each experiment
(3 days after the beginning of the treatment), the animals were killed
and the kidneys were removed. Cortex was dissected, snap frozen in
liquid nitrogen, and stored at 80 1C for total RNA and membrane
protein isolation.
Blood composition and urine analyses
Serum electrolytes, creatinine, and blood urea nitrogen levels
were measured using commercial services (LabOne of Ohio Inc.,
Cincinnati, OH, USA). Urinary excretion of Pi and calcium
was measured using phosphorus and calcium assay kits
(Pointe Scientific, Canton, MI, USA; http://www.pointescientific.
com).
Total RNA isolation and northern hybridization
Total RNA isolation. Total cellular RNA was extracted from
renal cortex by the method of Chomczynski and Sacchi.59 In brief,
cortical tissues were homogenized in Tri Reagent (Molecular
Research Center Inc., Cincinnati, OH, USA) at room temperature.
Total RNA was extracted by phenol/chloroform and precipitated by
isopropanol. Total RNA was quantitated by spectrophotometry and
stored at 80 1C.
Northern hybridization. Total RNA samples (30 mg/lane) were
fractionated on a 1.2% agarose–formaldehyde gel and transferred to
Magna NT nylon membranes using 10 sodium chloride–sodium
phosphate–EDTA as a transfer buffer. Hybridization was performed
according to Church and Gilbert60 and as previously used in our
laboratory.55,61,62 Membranes were hybridized overnight with
32P-labeled specific DNA probes (25 ng). The membranes were
washed, blotted, and exposed to Phosphor-imager cassette at room
temperature for 24–72 h, and read by Phosphor-imager (Molecular
Dynamics, Sunnyvale, CA, USA). Specific probes for various Pi
transporters, NHERF1 and klotho genes, were generated by reverse
transcription-PCR using total RNA from cortex as a template for
reverse transcription. PCR was performed using the following sets of
specific primers: rat NaPi-IIa: sense, 50-ACCTCTGTCACCAACAC
CAT-30; antisense, 50-TGAAGAAGAAGTGGCAGAGG-30; rat NaPi-
IIc: sense, 50-GAGGAACAGCTCAGCATCTCC-30; antisense, 50-CAGC
GGTATTGTGCAGTCAGG-30; rat PiT1: sense, 50-CATCTCGGTGG
GATGTGC-30; antisense, 50-TGTTGGTCTCCTCCTTCA-30; rat
klotho: sense, 50-TAAGGTTCAAGTATGGAGAC-30; antisense, 50-
GGGCGTTCACACTTATTTAT-30; rat NHERF1: sense, 50-CATCAG
CAGGTGGTGAGCCG-30; antisense, 50-CCATCCAGGTGCTCCTG
GGA-30. The PCR products were then separated on 1.2% agarose
gels containing ethidium bromide and visualized under an
ultraviolet illuminator. The expected DNA fragment was verified
by DNA sequencing using commercial services (DNA Core,
University of Cincinnati, Cincinnati, OH, USA).
Membrane protein isolation and immunoblotting
Preparation of membrane fractions. A total cellular fraction
containing plasma membrane and intracellular membrane proteins
was prepared from cortex as previously described.61,62 The total
protein concentration was measured using BCA protein assay kit
(Pierce, Rockford, IL, USA; http://www.piercenet.com), and mem-
brane fractions were solubilized at 65 1C for 20 min in Laemmli
buffer and stored at 20 1C.
Electrophoresis and immunoblotting. Semiquantitative im-
munoblotting experiments were carried out as previously
described.61,62 Briefly, the solubilized membrane proteins were size
fractionated on 10% polyacrylamide minigels (Novex, San Diego,
CA, USA) and transferred electrophoretically to a nitrocellulose
membrane. The membrane was blocked with 5% milk proteins, and
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then probed with affinity-purified antibody.61,62 The secondary
antibody was a donkey anti-rabbit IgG conjugated to horseradish
peroxidase (Pierce). The site of antigen–antibody complexation on
the nitrocellulose membranes was visualized using chemilumines-
cence method (Super Signal Substrate; Pierce) and captured on
light-sensitive imaging film (Kodak). The equity in protein loading
in all blots was first verified by gel staining using the Coomassie
brilliant blue R-250 (Bio-Rad, Hercules, CA, USA).
Materials
32P-dCTP was purchased from New England Nuclear (Boston, MA,
USA). Paper blotting nitrocellulose membranes used for northern
hybridization were purchased from Midwest Scientific (St Louis,
MO, USA) (http://www.midsci.com). ICI182,780 was purchased
from Tocris (Ellisville, MO, USA) (http://www.tocris.com). 17b-
Estradiol, progesterone, and all other chemicals were purchased
from Sigma Chemical Co. (St Louis, MO, USA) (http://www.
sigmaaldrich.com). High Prime DNA labeling kit was purchased
from Roche Diagnostics GmbH (Mannheim, Germany). Rabbit
polyclonal NaPi-IIa antiserum was generated and used as described
before.63,64 NHE3 and AQP-1 antibodies were purchased
from Alpha Diagnostic International (San Antonio, TX, USA)
(http://www.4adi.com).
Statistical analysis
Semiquantification of immunoblot and northern hybridization
band densities was determined by densitometry using a scanner
(ScanJet ADF; Hewlett Packard) and UN-SCAN-IT gel software
(Silk Scientific Inc., Orem, UT, USA) and ImageQuaNT software
(Molecular Dynamics), respectively. Data were expressed as % of
control. Results were presented as means±s.e. Statistical significance
between control and experimental groups was determined by one-
way analysis of variance or Student’s unpaired t-test as needed.
Po0.05 was considered significant.
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